Trinidad and Tobago

Population 2017: 1.4 million

<table>
<thead>
<tr>
<th>Estimation of TB burden*, 2017</th>
<th>Number (thousands)</th>
<th>Rate (per 100,000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mortality (excludes HIV+TB)</td>
<td>0.022 (0.02–0.025)</td>
<td>1.8 (1.4–1.8)</td>
</tr>
<tr>
<td>Mortality (HIV+TB only)</td>
<td>&lt;0.01 (&lt;0.01–&lt;0.01)</td>
<td>0.39 (0.29–0.51)</td>
</tr>
<tr>
<td>Incidence (includes HIV+TB)</td>
<td>0.23 (0.2–0.27)</td>
<td>17 (14–19)</td>
</tr>
<tr>
<td>Incidence (HIV+TB only)</td>
<td>0.031 (0.026–0.036)</td>
<td>2.3 (1.9–2.6)</td>
</tr>
<tr>
<td>Incidence (MDR/RR-TB)**</td>
<td>&lt;0.01 (&lt;0.01–0.015)</td>
<td>0.65 (0.33–1.1)</td>
</tr>
</tbody>
</table>

Estimates of TB burden and incidence by age and sex (thousands)*, 2017

<table>
<thead>
<tr>
<th>Age Group</th>
<th>Females (0.013–0.014)</th>
<th>Males (0.013–0.014)</th>
<th>Total (0.026–0.029)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0-14 years</td>
<td>0.013</td>
<td>0.014</td>
<td>0.027</td>
</tr>
<tr>
<td>&gt;14 years</td>
<td>0.013</td>
<td>0.014</td>
<td>0.027</td>
</tr>
<tr>
<td>Total</td>
<td>0.027</td>
<td>0.027</td>
<td>0.054</td>
</tr>
</tbody>
</table>

TB case notifications, 2017

- Total cases notified: 217
- Total new and relapse: 200
  - % tested with rapid diagnostics at time of diagnosis: 58%
  - % with known HIV status: 100%
  - % pulmonary: 96%
  - % bacteriologically confirmed among pulmonary: 63%

Universal health coverage and social protection

- TB treatment coverage (notified/estimated incidence), 2017: 87% (75–100)
- TB patients facing catastrophic total costs: 0.12 (0.1–0.14)
- TB/HIV care in new and relapse TB patients, 2017:
  - Number (24): 12%
  - on antiretroviral therapy (8): 33%

Drug-resistant TB care, 2017

- Estimated MDR/RR-TB cases among notified pulmonary TB cases: 7(4–11)
- Estimated % of TB cases with MDR/RR-TB: 2.3% (0.79–4.5)
- % notified tested for rifampicin resistance: 55%
- % with known HIV-status: 100%
- % antibiotic resistant: 13% (8.4–18)
- MDR/RR-TB cases tested for resistance to second-line drugs: 1
- Laboratory-confirmed cases (MDR/RR-TB: 2; XDR-TB: 0)
- Patients started on treatment ****
  - MDR/RR-TB: 2; XDR-TB: 0

TB financing, 2018

- National TB budget (US$ millions)
- Ranges represent uncertainty intervals
- ** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
- *** Includes cases with unknown previous TB treatment history
- **** Includes patients diagnosed before 2017 and patients who were not laboratory-confirmed

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

Generated: 2018-10-16

Data: www.who.int/tb/data